The field of medicine has without a doubt greatly benefited from the many advancements in technology that have been witnessed in the last two or three decades. Diagnosis, surgery and treatment have not only become easier for the doctors, but also for patients. The treatment of prostate cancer is one such field that has seen immense growth through technology.
The removal of cancerous prostates using the Robotic Prostatectomy method is one the most advanced as it involves the use of fibre optics from start to finish. At the forefront of Robotic Prostatectomy is Dr. David Samadi, a renowned surgeon and urologist. Dr David Samadi is widely known for having developed his signature technique known as the Samadi Modified Advanced Robotic Technique (SMART) which brings together the principles of oncology and open radical prostatectomy to build an innovative robotic surgery technique.
Using the SMART technique, Dr. David Samadi is able to target specific cancerous prostates and remove them while leaving behind minimal risk of complications from damage in the tissues neighboring the affected area. This also ensures there is minimum scarring and side effects that would arise from other tumor removal methods like radiation therapy or chemotherapy.
The SMART technique goes to ahead to guarantee minimal blood loss and pain during and after the procedure. The patient is able to leave the hospital a day after the surgery for further recuperation at home. The success rate for this technique is high, as studies have shown that over 88% of the patients who have undergone this method of treatment fully recover within months. Most patients have also reported full return to their normal routine, including sexual potency and urinary control.
Dr David Samadi is a certified urologist and oncologist who specializes in minimally invasive methods of cancer treatment, most notably prostate cancer. He is known to have carried out over 7000 surgeries. He also treats other urologic cancers and diseases. He holds a degree in biochemistry from Stony Brook University and an MD from the State University of New York, Stony Brook School of Medicine.
For More info: en.wikipedia.org/wiki/David_B._Samadi
Eric Lefkofsky helped created a company called Tempus because he wanted to make a difference in the field of cancer. The company is helping physicians customize the treatments used for cancer with genomic sequencing. Through their funding for series C, Tempus has raised $70 million. This is a portion of the $130 million raised since the beginning of Tempus in 2015. Eric Lefkofsky is the biggest individual investor for Tempus, and has donated to every fundraising effort. He has stated he is willing to make investments totaling $100 million to Tempus.
Eric Lefkofsky became aware of the hole in the infrastructure for collecting data regarding cancer. Using technology, his can compile the clinical, and genomic data of previous cancer patients. This allows for a more personalized treatment program for physicians. His realization of the lack of data available for oncologists has resulted in a massive database to benefit cancer patients. Partnerships between Tempus, the Cleveland Clinic, the Duke University School of Medicine, and the Mayo Clinic have formed within the last year. This improves the care available for cancer with a library comprised of molecular, and clinical data.
Eric Lefkofsky defines Tempus as a startup in health care, and technology capable of modernizing the treatments available for cancer with a modern infrastructure. Tempus works through Lightbank, a company founded by Eric Lefkofsky, and located in Chicago. Eric Lefkofsky is striving to help physicians make decisions regarding cancer treatments based on the genetic code of the individual patient. These decisions are driven by data, personalized, and reliant on molecular therapies. The genomic analysis, and sequencing used by Tempus reflects the cutting edge of technology.
Eric Lefkofsky’s work has provided physicians with proprietary algorithms, and genomic data, to locate the opportunities to make cancer treatments more precise, and effective. Physicians simply have a better treatment plan, and care opportunities with which to treat their patients. Tempus is currently working with patients with cancer of the lung, breast, and pancreas. Additional types of cancer are expected to be added over time. Tempus employs 29 individuals, and is making progress in their field of expertise.
In an interview by IdeaMensch dated April 14th, 2017 Clay Siegall provided great insight about his role as CEO of Seattle Genetics. Motivated by his father’s battle with cancer which began when he was only nineteen years old; Clay Siegall noticed that the resources doctor’s had been very limited. He eventually pursued a Ph.D. with George Washington University. While Siegall is certainly an entrepreneur, he credits himself as being a scientist first and foremost. His goal of helping patients with drugs that are targeted specifically to their needs has been in practice for thirty years. Recently, Seattle Genetics has been paving the way with antibody-drug conjugates, which have yielded a new drug called ADCTERIS, produced by Takeda Pharmaceutical Company. The company continues to develop proprietary drugs along these (same) lines.
Siegall’s business acumen has also made it possible to secure financing of over 1.2 billion dollars. His company was founded in 1998 and was made public in 2001. He is not only the CEO of Seattle Genetics but also on the board of directors at Mirna, a company focusing on microRNA therapeutics and Alder BioPharmaceuticals. Prior to starting his own company, Siegall worked for drug and research giant Bristol-Myers Squibb Pharmaceutical Research Institute and the National Cancer Institute, National Institutes of Health. To top off his already extensive resume, he has authored over 70 publications and has patented his work over 15 times.
Siegall’s work(s) have not gone unnoticed. He’s earned many accolades including 2013 Alumnus of the Year Award for Computer, Math, and Science(s) from the University of Maryland where he earned his B.S. in Zoology. He’s been distinguished as the Pacific Northwest Ernst & Young Entrepreneur of the Year in 2012. He’s also known for having partnered with many other pharmaceutical companies to make his technology and research widespread to make even faster advances. Siegall’s efforts, knowledge, and experience, as well as his business expertise, make him stand out among the Biotech and Pharmaceutical companies and his hard work and dedication are making rapid advances in cancer therapy possible.